You are here

OC-01

Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies

Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies

BioSpace

Oyster Point Pharma

Ji Xing Pharmaceuticals

dry eye disease

Flag link:

FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01

FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01

BioSpace

dry eye disease

Flag link:

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Endpoints

Oyster Point Pharma

dry eye disease

Flag link:

Oyster Point Pharma Files for $85 Million IPO

Oyster Point Pharma Files for $85 Million IPO

CP Wire

Oyster Point Pharma

dry eye disease

Flag link:

Oyster Point Pharma Files for $85 Million IPO

Oyster Point Pharma

dry eye disease

Flag link:

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

BioCentury

dry eye disease

Flag link:

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

BioCentury

dry eye disease

clinical trials

Flag link: